News
-
-
PRESS RELEASE
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) will conduct an investor webcast on April 1, 2024, at 8:30 a.m. EST to review fourth-quarter financials and corporate updates. Company plans to file its Earnings Report on Form 10-K for year ended December 31, 2023 -
-
PRESS RELEASE
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Jaguar Health, Inc. announces exclusive license agreement with GEN for crofelemer products in key territories, including payment of double-digit royalties. Agreement covers FDA-approved indications and potential follow-on uses -
-
PRESS RELEASE
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
Jaguar Health Provides Update on Nasdaq Listing Status. Company requests appeal hearing after receiving delisting notification. Working on comprehensive analysis of Phase 3 trial for cancer therapy-related diarrhea prevention -
PRESS RELEASE
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Animal Health announces agreement with FDA on clinical field study design for Canalevia-CA1, a canine-specific treatment for chemotherapy-induced diarrhea in dogs, towards full approval -
-
PRESS RELEASE
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Jaguar Health announces Orphan Drug Designation application for crofelemer for symptomatic relief and treatment of moderate-to-severe diarrhea caused by bacterial, viral, and parasitic infections, including cholera. Crofelemer is a novel plant-based prescription drug derived from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest -
PRESS RELEASE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
Magdalena Biosciences, Inc. plans to submit an Investigational New Drug application to the FDA in 2024 for a next-generation psychoactive prescription drug candidate targeting mental health indications such as ADHD, depression, and anxiety. The preclinical study in mice suggests psychoactive activity in a plant extract for potential use as a next-generation psychoactive prescription drug. Magdalena focuses on identifying safe and effective plant-based psychoactive drugs to treat mental health disorders
